
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Kala Pharmaceuticals Inc (KALA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: KALA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $13.5
1 Year Target Price $13.5
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.81% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.81M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 2 | Beta -1.98 | 52 Weeks Range 2.92 - 11.20 | Updated Date 06/30/2025 |
52 Weeks Range 2.92 - 11.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.51% | Return on Equity (TTM) -576.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19169243 | Price to Sales(TTM) 1.16 |
Enterprise Value 19169243 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 6452400 | Shares Floating 3685223 |
Shares Outstanding 6452400 | Shares Floating 3685223 | ||
Percent Insiders 2.11 | Percent Institutions 64.18 |
Analyst Ratings
Rating 2 | Target Price 13.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kala Pharmaceuticals Inc

Company Overview
History and Background
Kala Pharmaceuticals, Inc. was a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye diseases. Founded in 2009, it aimed to improve treatment paradigms for both front and back of the eye indications. Significant milestones included FDA approvals for its products. It has since ceased operations and liquidation is in progress.
Core Business Areas
- Pharmaceutical Development and Commercialization: Focused on researching, developing, and commercializing therapies for ocular diseases, particularly those affecting the front and back of the eye.
Leadership and Structure
Historically, Kala Pharmaceuticals had a CEO and a management team overseeing its operations. Details of the specific leadership team are not relevant as the company is ceasing operations.
Top Products and Market Share
Key Offerings
- Inveltys (loteprednol etabonate ophthalmic suspension) 1%: Indicated for the treatment of post-operative inflammation and pain following ocular surgery. Market share data unavailable due to the company ceasing operations. Competitors included other steroidal and non-steroidal anti-inflammatory drugs for post-operative inflammation, such as those from Allergan (now AbbVie) and Novartis.
- Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%: Indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Market share data unavailable due to the company ceasing operations. Competitors included Restasis and Xiidra and other dry eye treatments from companies like Novartis and Allergan (now AbbVie).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in ophthalmology, is characterized by significant competition and a focus on developing innovative treatments for various eye diseases. There is high demand due to the aging population and prevalence of conditions like dry eye and glaucoma.
Positioning
Historically, Kala Pharmaceuticals positioned itself as a developer of differentiated ophthalmic therapies using its proprietary mucus-penetrating particle (MPP) technology. Its ceased operations meant their position is no longer active.
Total Addressable Market (TAM)
The global ophthalmic drug market is substantial, reaching billions of dollars annually. Kala Pharmaceuticals aimed to capture a portion of this market with its products, but the company's ceased operations impacts it's market reach.
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
- ABBV
- NVS
Competitive Landscape
Kala Pharmaceuticals faced intense competition from larger, established pharmaceutical companies with broader portfolios and greater resources. Its ceased operations reflects its inability to compete effectively in the long term.
Growth Trajectory and Initiatives
Historical Growth: Kala Pharmaceuticals had revenue growth periods following FDA approvals, but the company ultimately faced financial challenges and ceased operations.
Future Projections: There are no future growth projections due to the company ceasing operations.
Recent Initiatives: Recent initiatives included cost-cutting measures and attempts to secure financing, which ultimately failed to prevent the company's closure.
Summary
Kala Pharmaceuticals, once a promising biopharmaceutical company, ultimately failed to achieve sustainable profitability and ceased operations. Its core products, Inveltys and Eysuvis, faced significant competition. The company's struggles highlight the challenges of developing and commercializing ophthalmic therapies. Investors should be aware that KALA stock is no longer an active security.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Industry Reports
- Company website archives
Disclaimers:
This analysis is based on publicly available information and historical data. The information is provided for informational purposes only and should not be considered financial advice. As the company has ceased operations, the information is for historical purposes only and should not be used to make investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kala Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Arlington, MA, United States | ||
IPO Launch date 2017-07-20 | Interim CEO, President & COO Mr. Todd Bazemore | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.kalarx.com |
Full time employees 38 | Website https://www.kalarx.com |
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.